Oragenics, Inc.
$0.71
▲
2.24%
2026-04-21 08:36:00
www.oragenics.com
ASE: OGEN
Explore Oragenics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.19 M
Current Price
$0.71
52W High / Low
$9.6 / $0.5
Stock P/E
—
Book Value
$1.94
Dividend Yield
—
ROCE
-113.05%
ROE
-2.44%
Face Value
—
EPS
$-4.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
3
Beta
1.21
Debt / Equity
2.75
Current Ratio
5.64
Quick Ratio
5.64
Forward P/E
-0.06
Price / Sales
—
Enterprise Value
$-5.56 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Editas Medicine, Inc. | $3.57 | — | $349.4 M | — | -70.81% | -1.98% | $4.54 / $1.23 | $0.28 |
| 2. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 3. | Moderna, Inc. | $55.11 | — | $21.94 B | — | -29.7% | -28.87% | $59.55 / $22.28 | $21.95 |
| 4. | AnaptysBio, Inc. | $50.95 | — | $1.46 B | — | 14.7% | -24.49% | $73.3 / $17.11 | $1.33 |
| 5. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
| 6. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 7. | Design Therapeutics, Inc. | $13.16 | — | $809.14 M | — | -37.28% | -30.7% | $13.5 / $3.1 | $3.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.5 M | -3.12 M | -1.71 M | -2.03 M | -3.36 M | — |
| Net Profit | -2.29 M | -3.07 M | -2.27 M | -2.22 M | -3.35 M | — |
| EPS in Rs | -0.53 | -0.71 | -0.52 | -0.51 | -0.77 | -11.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -9.36 M | -10.56 M | -20.9 M | -14.42 M |
| Net Profit | -9.84 M | -10.57 M | -20.66 M | -14.29 M |
| EPS in Rs | -2.27 | -2.44 | -4.76 | -3.3 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 10.07 M | 1.47 M | 4.97 M | 14.76 M |
| Total Liabilities | 1.79 M | 1.68 M | 1.8 M | 1.75 M |
| Equity | 8.28 M | -0.21 M | 3.17 M | 13.01 M |
| Current Assets | 10.07 M | 1.47 M | 3.87 M | 14.29 M |
| Current Liabilities | 1.79 M | 1.68 M | 1.8 M | 1.6 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.25 M | -8.6 M | -7.29 M | -15.23 M |
| Investing CF | — | 0 M | -0.94 M | -0.12 M |
| Financing CF | 16.78 M | 5.98 M | 0.28 M | -0.49 M |
| Free CF | -9.25 M | -8.6 M | -8.29 M | -15.36 M |
| Capex | — | — | -1 M | -0.13 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 48.84% | -44.56% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-03 | 1:0.0333333 |
| 2023-01-23 | 1:0.0166667 |